89Zr-ss-pertuzumab Imaging for Breast Cancer

Recruiting in Palo Alto (17 mi)

+7 other locations

Overseen byRandy Yeh, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?The purpose of this study is to see whether 89Zr-ss-pertuzumab is safe in people with HER2+ cancer.

Eligibility Criteria

This trial is for adults over 18 with HER2+ breast cancer, as defined by specific medical guidelines or genetic testing. Participants must have at least one detectable cancer lesion and be in fair to good physical condition (ECOG 0-2). Pregnant or breastfeeding individuals, those with certain kidney or liver conditions, a life expectancy under three months, or who exceed the weight limit for PET/CT scans cannot join.

Inclusion Criteria

I am 18 years old or older.

My cancer is HER2 positive based on specific guidelines or tests.

My cancer has low HER2 levels, confirmed by specific tests.

+3 more

Exclusion Criteria

Your liver enzymes (AST/ALT) are more than double the normal limit.

Pregnancy or lactation

Your kidney function, measured by a blood test called creatinine, is more than double the normal level.

+2 more

Participant Groups

The study is evaluating the safety of a new imaging agent called 89Zr-ss-pertuzumab used in PET/CT scans to identify cancer in patients with HER2+ breast cancer. It aims to determine if this agent can effectively highlight tumors during imaging.

2Treatment groups

Experimental Treatment

Group I: HER2-positive malignancyExperimental Treatment1 Intervention

Participants will have a diagnosis of HER2-positive malignancy

Group II: HER2-low malignancyExperimental Treatment1 Intervention

Participants will have a diagnosis of HER2-low malignancy